BioXcel Therapeutics Inc (NASDAQ:BTAI) price closed higher on Friday, April 12, jumping 3.94% above its previous close.
A look at the daily price movement shows that the last close reads $2.79. The company’s 5Y monthly beta was ticking 0.39. Taking into account the 52-week price action we note that the stock hit a 52-week high of $29.56 and 52-week low of $1.91. The stock added 1.05% on its value in the past month.
BioXcel Therapeutics Inc, which has a market valuation of $97.53 million, is expected to release its quarterly earnings report May 06, 2024 – May 10, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give BTAI a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
The overview shows that BTAI’s price is at present 5.63% off the SMA20 and -2.78% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 54.18, with weekly volatility standing at 6.42%. The indicator jumps to 6.64% when calculated based on the past 30 days. BioXcel Therapeutics Inc (NASDAQ:BTAI)’s beta value is holding at 0.39, while the average true range (ATR) indicator is currently reading 0.20. An analysis of the BioXcel Therapeutics Inc (NASDAQ:BTAI) stock in terms of its daily trading volume indicates that the 3-month average is 1.54 million.
Current records show that the company has 29.93M in outstanding shares. The insiders’ percentage holdings are 26.96% of outstanding shares while the percentage share held by institutions stands at 28.05%. But the -1.69% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
